RxDoctor Payments Data

David Holland, MD

Internal Medicine · Shawnee, OKNPI 1831147255

Payments from drug & device makers

$398in general payments, 2019–2025

Across 19 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$101
  • AstraZeneca$72
  • Novo Nordisk$40
  • Pfizer$34
  • RGH Enterprises LLC$25
  • Amgen$23
  • plus $102 from 6 others

What the payments were for

  • Food & beverage$38497%
  • Education$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$398 in reported general payments places this provider in the 55th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$96,463
Medicare patients
588
Services billed
1,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$200,716
JardianceEmpagliflozin188$197,274
JanuviaSitagliptin Phosphate97$110,062
EliquisApixaban131$99,704
XareltoRivaroxaban91$65,728
TrulicityDulaglutide59$64,389
MounjaroTirzepatide39$41,798
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$40,838
FarxigaDapagliflozin Propanediol64$39,498
RybelsusSemaglutide29$33,654
Xtampza ErOxycodone Myristate14$28,879
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen502$11,868
JanumetSitagliptin Phos/Metformin Hcl15$11,680
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$11,575
Atorvastatin Calcium644$8,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$40$234,371181 claims
Boehringer IngelheimJardiance, Combivent Respimat$18$202,588199 claims
Lilly USA, LLCTrulicity, Mounjaro$15$106,18798 claims
PfizerEliquis$34$99,704131 claims
AstraZenecaFarxiga, Symbicort$72$47,19491 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Shawnee

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →